The Centers for Medicare & Medicaid Services today issued an advance notice of proposed rulemaking seeking comments through Dec. 31 on potential options the agency may consider for testing changes to payment for certain separately payable Part B drugs and biologicals.
 
Specifically, CMS intends to test whether phasing down the Medicare payment amount for selected Part B drugs to more closely align with international prices; allowing private-sector vendors to negotiate prices for drugs, take title to drugs, bill Medicare for the drugs and compete for physician and hospital business; and changing the 4.3 percent (post-sequester) drug add-on payment in the model to reflect 6 percent of historical drug costs translated into a set payment amount, would lead to higher quality of care for beneficiaries and reduced expenditures to the Medicare program. Hospitals and physicians would continue to receive payment for drug administration plus a new "drug add-on" payment. CMS is considering issuing a proposed rule next spring on the potential model, called the International Pricing Index Model. The model would start in spring 2020 and operate for five years. Over the course of the model, CMS would monitor and evaluate the impact on beneficiary access to drugs, program costs, and the quality of care for beneficiaries. Participation in the IPI model would be mandatory for physician practices, hospital outpatient departments, and potentially other Part B providers and suppliers that furnish the model's included drugs in the selected geographic areas. For more information, see the CMS factsheet.
 
"America's hospitals and health systems are pleased that President Trump and his administration are focused on reining in out-of-control drug prices, which continue to threaten patient access and the ability of providers to deliver the highest quality of care," said AHA President and CEO Rick Pollack in a statement. "We look forward to reviewing the details of the model closely, including its impact on 340B hospitals and the patients they serve."
 
The Department of Health and Human Services also released a report today comparing the prices paid for physician-administered drugs in the U.S. to certain other countries.


 

Related News Articles

Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…
Headline
The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures.  Witness Ge Bai, an…
Headline
The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…